Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Short term Debt data on record, last reported at $13.5 million in Q3 2025.

  • For Q3 2025, Short term Debt fell 8.34% year-over-year to $13.5 million; the TTM value through Sep 2025 reached $13.5 million, down 8.34%, while the annual FY2024 figure was $15.0 million, 206.31% up from the prior year.
  • Short term Debt reached $13.5 million in Q3 2025 per RANI's latest filing, down from $15.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $15.0 million in Q4 2024 and bottomed at $30000.0 in Q2 2022.
  • Average Short term Debt over 5 years is $7.7 million, with a median of $8.6 million recorded in 2024.
  • Peak YoY movement for Short term Debt: fell 13.1% in 2021, then surged 2121.82% in 2023.
  • A 5-year view of Short term Debt shows it stood at $126000.0 in 2021, then plummeted by 56.35% to $55000.0 in 2022, then soared by 8803.64% to $4.9 million in 2023, then soared by 206.31% to $15.0 million in 2024, then fell by 9.75% to $13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $13.5 million in Q3 2025, $15.0 million in Q2 2025, and $15.0 million in Q1 2025.